智通财经APP获悉，艾美疫苗(06660)涨近5%，截至发稿，涨4.93%，报7.88港元，成交额5153.23万港元。
消息面上，艾美疫苗发布公告称，公司自主研发的13价结合肺炎疫苗已向国家药品监督管理局提交药品上市注册。已完成揭盲的Ⅲ期临床研究结果显示，艾美这款疫苗具有良好的免疫原性和安全性，达到临床预设目标。此外，集团旗下艾美坚持生物制药有限公司已取得生产该产品相应的药品生产许可证。
此前，公司宣布控股子公司珠海丽凡达生物技术有限公司研发的mRNA呼吸道合胞病毒(RSV)疫苗已于近日获得国家药监局出具的《药物临床试验批准通知书》，标志着该疫苗的研发进入了新的阶段。公司表示将加速推进mRNA呼吸道合胞病毒(RSV)疫苗的临床试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.